首页 | 本学科首页   官方微博 | 高级检索  
     

非体外循环冠状动脉旁路移植术后的阿司匹林抵抗
引用本文:王赞鑫,高菲,任静,门剑龙,魏民新. 非体外循环冠状动脉旁路移植术后的阿司匹林抵抗[J]. 中华胸心血管外科杂志, 2011, 27(8). DOI: 10.3760/cma.j.issn.1001-4497.2011.08.010
作者姓名:王赞鑫  高菲  任静  门剑龙  魏民新
作者单位:1. 300052,天津医科大学总医院心血管外科
2. 300052,天津医科大学总医院临床检验科
基金项目:天津市应用基础研究计划重点项目,天津市卫生局科技基金
摘    要:目的 通过检测非体外循环冠状动脉旁路移植术(OPCAB)后患者血小板聚集率以及尿11-脱氢-血栓烷B2(11-DH-TXB2)指标,动态观察术后阿司匹林抵抗(AR)的发生情况,探索术后AR的危险因素。方法 冠心病患者290例,首次行OPCAB患者145例(手术组),接受内科药物治疗患者145例(非手术组)。手术组患者于术前及术后服用阿司匹林后第1、4、10天及6个月,检测血小板聚集率以及尿11-DH-TXB2。非手术组患者于服药前及服药后第1、4、10天检测上述指标。同时记录患者各项临床资料。结果 手术组患者服用阿司匹林后第1天的AR发生46例(32%)(抵抗组),其余为非抵抗组。用药后第4天和第10天AR患者下降至19例(13%)和5例(3%)。半年随访中未发现有AR患者存在。非手术组患者,服药后第1天,血小板聚集率均下降至20%以下,平均(8.8±6.8)%,未见AR现象出现。手术组患者术后血小板计数显著高于术前(P<0.05)。Logistic回归分析发现,OPCAB患者中,体重大于75 kg(OR =0.38,95%CI:0.18~0.79)和术后引流量超过500 ml(OR=3.12,95%CI:1.29~7.53)为术后出现AR的危险因素。结论 OPCAB术后早期,阿司匹林的抗血小板作用受到不同程度抑制,部分患者出现AR现象,予以更为积极有效的抗血小板治疗有重要临床意义。

关 键 词:阿司匹林  冠状动脉旁路移植术  非体外循环  血小板聚集  血栓烷B2

Aspirin resistance after off-pump coronary artery bypass graft surgery
WANG Zan-xin,GAO Fei,REN Jing,MEN Jian-long,WEI Min-xin. Aspirin resistance after off-pump coronary artery bypass graft surgery[J]. Chinese Journal of Thoracic and Cardiovascular Surgery, 2011, 27(8). DOI: 10.3760/cma.j.issn.1001-4497.2011.08.010
Authors:WANG Zan-xin  GAO Fei  REN Jing  MEN Jian-long  WEI Min-xin
Abstract:Objective The present study was designed evaluate the aspirin effectiveness in the inhibition of platelet aggregation in patients after OPCAB.Methods 290 patients were recruited.145 patients underwent first time OPCAB (surgery group).Arachidonic acid induced platelet aggregation and urine 11-dehydro thromboxane B2 (11-dehydroTxB2) were measured before operation and on aspirin re-administered days 1,4, 10, and 6 months after surgery.The same tests were also detected in 145 patients from the cardiology department (non-surgery group) received medicine therapy as controls.Results Ninety-nine patients were defined as aspirin sensitive after OPCAB (AS Group).Postoperative aspirin resistance was identified in 46 (32%) patients at the first day after aspirin treatment started (AR Group).19 (13%) and 5 (3%) patients remained as AR at day 4 and 10 after aspirin re-administration, respectively.Patients in the AR group had higher 11-dehydroTxB2 levels than those in the AS group (P = 0.049).Six months follow-up showed ARA-induced platelet aggregation was (11.5 ± 3.4) %.Urine level of 11-dehydroTxB2 was (50.3 ± 15.4) ng/L.No resistance was found.All cardiologic patients were identified as aspirin sensitive, the change of platelet aggregation and 11-dehydroTxB2 were similar as those in the AS group.Weight >75 kg and postoperative drainage >500 ml were risk factors of aspirin resistance after OPCAB.Conclusion Anti-platelet effect of aspirin was reduced during the early postoperative period in certain patients undergoing OPCAB.In case of resistance,antiplatelet treatment strategy should be intensified or modified.
Keywords:Aspirin  Coronary artery bypass graft off-pump  Platelet aggregation  Thromboxane B2
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号